Paper41344992
TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.
Sponheimer M and 28 others. J Immunother Cancer, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity. Papers, record 41344992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41344992
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| CD27 Ligand | Major topic |
| Tumor Necrosis Factor-alpha | Major topic |
| Antibody-Dependent Cell Cytotoxicity | Major topic |
| Interferon-gamma | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Mice, SCID | |
| Female | |
| Male | |
| Cell Line, Tumor | |
| Xenograft Model Antitumor Assays | |
| Killer Cells, Natural |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38943249 | NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody. | Mol Ther | 2024 | https://conductscience.org/library/papers/38943249 | PubMed |
| 2 | 17538161 | Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17538161 | PubMed |
| 3 | 30024784 | CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/30024784 | PubMed |
| 4 | 30275109 | Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. | Blood | 2018 | https://conductscience.org/library/papers/30275109 | PubMed |
| 5 | 31826340 | Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31826340 | PubMed |
| 6 | 28031480 | CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. | J Exp Med | 2017 | https://conductscience.org/library/papers/28031480 | PubMed |
| 7 | 33052757 | ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33052757 | PubMed |
| 8 | 32601337 | Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. | Nat Med | 2020 | https://conductscience.org/library/papers/32601337 | PubMed |
| 9 | 36416736 | Allogeneic natural killer cell therapy. | Blood | 2023 | https://conductscience.org/library/papers/36416736 | PubMed |
| 10 | 30555165 | Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. | Leukemia | 2019 | https://conductscience.org/library/papers/30555165 | PubMed |
| 11 | 29707140 | A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. | Oncotarget | 2018 | https://conductscience.org/library/papers/29707140 | PubMed |
| 12 | 21841316 | Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. | J Clin Invest | 2011 | https://conductscience.org/library/papers/21841316 | PubMed |
| 13 | 34991665 | The CD70-CD27 axis in oncology: the new kids on the block. | J Exp Clin Cancer Res | 2022 | https://conductscience.org/library/papers/34991665 | PubMed |
| 14 | 24300852 | CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. | Blood | 2014 | https://conductscience.org/library/papers/24300852 | PubMed |
| 15 | 19062317 | Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. | Immunity | 2008 | https://conductscience.org/library/papers/19062317 | PubMed |
| 16 | 22863621 | Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. | J Clin Invest | 2012 | https://conductscience.org/library/papers/22863621 | PubMed |
| 17 | 36758420 | Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. | Gynecol Oncol | 2023 | https://conductscience.org/library/papers/36758420 | PubMed |
| 18 | 22031859 | IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. | Blood | 2011 | https://conductscience.org/library/papers/22031859 | PubMed |
| 19 | 26942060 | Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. | Oncoimmunology | 2016 | https://conductscience.org/library/papers/26942060 | PubMed |
| 20 | 25186908 | OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines. | Genome Res | 2014 | https://conductscience.org/library/papers/25186908 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42398968 | Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42398968 | PubMed |
| 42035126 | Bispecific CD37-Siglec6 CAR‑T cells exhibit enhanced anti‑leukemic activity and reduced exhaustion in acute myeloid leukemia xenograft models. | J Transl Med | 2026 | https://conductscience.org/library/papers/42035126 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41344992
GET https://conductscience.org/api/papers/v1/41344992/authors?page=2